Since our founding in 1973, Nihon Medi-Physics has worked alongside healthcare professionals to advance nuclear medicine in Japan. Guided by our purpose of helping create a healthier society through nuclear medicine, we have continued to develop our expertise as a leading radiopharmaceutical company, supporting disease detection and diagnosis for patients across the country.

In 2025, we began a new chapter as part of GE HealthCare. By combining the proven track record, scientific expertise, and trusted relationships Nihon Medi-Physics has cultivated in Japan, with GE HealthCare’s global scale, long history of innovation, and deep experience in Pharmaceutical Diagnostics, we are confident that we can deliver even more meaningful value to patients, healthcare professionals, customers and society.

GE HealthCare’s Pharmaceutical Diagnostics (PDx) division meets the needs of healthcare professionals and patients worldwide through two powerful offerings: radiopharmaceuticals and contrast media. As a member of this division, Nihon Medi-Physics will continue to build on its strong foundation in Japan, while contributing to the advancement of radiopharmaceuticals across Japan and the East Asia region.

Looking ahead, we are committed to expanding patient access to innovative radiopharmaceuticals, strengthening our ability to support disease detection and diagnosis, and helping realize GE HealthCare’s vision of creating a world where healthcare has no limits. 

We pledge to continue working to deliver the future of healthcare and contribute to a healthier society.

Representative Directors
Maggie Xiao / Nobuyuki Takahashi